Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003389 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 854
- Enrollment target
NCT00003389 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 854 participants.
The verdict
NCT00003389, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 854 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining more than one drug with radiation therapy may kill more cancer cells. It is not yet known which combination chemotherapy regimen is most effective in treating Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well they work, with or without radiation therapy, in treating patients with Hodgkin's lymphoma.
Interventions
- DRUG Doxorubicin
- DRUG Vincristine
- DRUG Dacarbazine
- DRUG Vinblastine
- DRUG Bleomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 854 participants |
| Start Date | 1999-06-17 |
| Est. Completion | 2016-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003389
The ClinicalTrials.gov registry entry for NCT00003389 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 854 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Doxorubicin is the first listed.
NCT00003389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003389 about?
NCT00003389 is a clinical study titled "Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining more than one drug with radiation therapy may kill more cancer cells. It is not yet known which combina...
What is the current status of trial NCT00003389?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 854 participants. The study started on 1999-06-17. Estimated completion is 2016-05.
What interventions are being tested in trial NCT00003389?
The interventions under investigation include: Doxorubicin (DRUG), Vincristine (DRUG), Dacarbazine (DRUG), Vinblastine (DRUG), Bleomycin (DRUG).
Who is sponsoring clinical trial NCT00003389?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.